AlzeCure Pharma AB (publ) announced that the company will hold a live expert event on February 19 with Professor Henrik Zetterberg as special expert guest speaker. AlzeCure's Alzstatin platform consists of potent and selective GSMs that have been shown to reduce the production of toxic A42 oligomers by more than 60% in preclinical models of Alzheimer's disease, without impacting other signalling pathways controlled by gamma-secretase, a major limitation of first-generation gamma-secretase inhibitors (GSIs). AlzeCure's GSMs concurrently increase the production of A37 and A38, which have shown protective properties by preventing A aggregation.

The Alztatin program will benefit from the clinical development path being layed out by Roche which also has a GSM in development, RG6289, demonstrating big pharma validation and interest in the mechanism. At the recent CTAD conference, Roche presented phase I clinical data for RG6289, showing proof-of-mechanism and a good safety profile. AlzeCure's NeuroRestore (Trk-PAM) program is designed to improve cognition in Alzheimer's disease and other CNS disorders, with data also suggesting potential disease-modifying effects.

The program has demonstrated a good safety profile and target engagement in phase I and is in preparation for phase II studies.